DE69333563D1 - Substituierte Azetidinone als entzüngdungshemmende und antidegenerative Wirkstoffe - Google Patents

Substituierte Azetidinone als entzüngdungshemmende und antidegenerative Wirkstoffe

Info

Publication number
DE69333563D1
DE69333563D1 DE69333563T DE69333563T DE69333563D1 DE 69333563 D1 DE69333563 D1 DE 69333563D1 DE 69333563 T DE69333563 T DE 69333563T DE 69333563 T DE69333563 T DE 69333563T DE 69333563 D1 DE69333563 D1 DE 69333563D1
Authority
DE
Germany
Prior art keywords
chem
inflammatory
substituted azetidinones
agents
degenerative agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69333563T
Other languages
English (en)
Other versions
DE69333563T2 (de
Inventor
James B Doherty
Paul E Finke
Conrad P Dorn
Malcolm Maccoss
Philippe L Durette
Sander G Mills
Shrenik K Shah
Thomas J Lanza
Soumya P Sahoo
William K Hagmann
Jeffrey J Hale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Application granted granted Critical
Publication of DE69333563D1 publication Critical patent/DE69333563D1/de
Publication of DE69333563T2 publication Critical patent/DE69333563T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DE69333563T 1992-10-27 1993-10-22 Substituierte Azetidinone als entzüngdungshemmende und antidegenerative Wirkstoffe Expired - Lifetime DE69333563T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96680092A 1992-10-27 1992-10-27
US99183892A 1992-12-17 1992-12-17
US966800 1992-12-17
US991838 1992-12-17

Publications (2)

Publication Number Publication Date
DE69333563D1 true DE69333563D1 (de) 2004-08-05
DE69333563T2 DE69333563T2 (de) 2005-08-18

Family

ID=27130493

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69333563T Expired - Lifetime DE69333563T2 (de) 1992-10-27 1993-10-22 Substituierte Azetidinone als entzüngdungshemmende und antidegenerative Wirkstoffe

Country Status (29)

Country Link
EP (1) EP0595557B1 (de)
JP (1) JPH082868B2 (de)
KR (1) KR950704250A (de)
CN (1) CN1043884C (de)
AT (1) ATE270273T1 (de)
AU (1) AU663806B2 (de)
CA (1) CA2108584C (de)
CY (1) CY2529B1 (de)
CZ (1) CZ106895A3 (de)
DE (1) DE69333563T2 (de)
DK (1) DK0595557T3 (de)
DZ (1) DZ1724A1 (de)
ES (1) ES2224095T3 (de)
FI (1) FI951992A (de)
HR (1) HRP931309A2 (de)
HU (2) HUT72084A (de)
IL (1) IL107321A (de)
LV (1) LV13338B (de)
MX (1) MX9306666A (de)
MY (1) MY128261A (de)
NO (1) NO305697B1 (de)
NZ (1) NZ257755A (de)
PL (1) PL308545A1 (de)
PT (1) PT595557E (de)
RU (1) RU2148056C1 (de)
SI (1) SI9300566A (de)
SK (1) SK53795A3 (de)
TW (1) TW275621B (de)
WO (1) WO1994010142A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5420010A (en) * 1993-07-30 1995-05-30 Merck & Co., Inc. Assay for evaluating inhibition of polymorphonuclear leukocyte elastase by N-substituted azetidinones
AU5014496A (en) * 1995-03-23 1996-10-08 Japan Tobacco Inc. Diphenylmethyl-azetidinone compounds and elastase inhibitor
US5523233A (en) * 1995-05-03 1996-06-04 Merck & Co., Inc. Enzymatic hydrolysis of 3,3-diethyl-4-[(4-carboxy)phenoxy]-2-azetidinone esters
JP3081250B2 (ja) * 1995-10-31 2000-08-28 メルク エンド カンパニー インコーポレーテッド 置換アゼチジノンの製造方法
US5808056A (en) * 1995-10-31 1998-09-15 Merck & Co., Inc. Process for preparing substituted azetidinones
EP0869943A1 (de) * 1995-12-08 1998-10-14 Smithkline Beecham Plc Monocyclische beta-lactame zur behandlung von atherosklerose
JP2000509049A (ja) * 1996-04-26 2000-07-18 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー アテローム性動脈硬化症の治療用アゼチジノン誘導体
EP1099690A4 (de) * 1998-07-23 2001-10-17 Shionogi & Co Monozyklische beta-lactamverbindungen und chymase inhibitoren, die diese enthalten
RU2217196C2 (ru) * 2002-02-28 2003-11-27 Небольсин Владимир Евгеньевич Способ индукции дифференцировки клеток
FR2937972B1 (fr) * 2008-11-04 2013-03-29 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique
SG173865A1 (en) * 2009-03-09 2011-09-29 Taiho Pharmaceutical Co Ltd Piperazine compound capable of inhibiting prostaglandin d synthase
FR2981933B1 (fr) * 2011-11-02 2013-11-15 Galderma Res & Dev Derives d'oxoazetidine, leur procede de preparation et leur utilisation en medecine humaine ainsi qu'en cosmetique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ228600A (en) * 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
IL99658A0 (en) * 1990-10-15 1992-08-18 Merck & Co Inc Substituted azetidinones and pharmaceutical compositions containing them
WO1993000332A1 (en) * 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents

Also Published As

Publication number Publication date
DE69333563T2 (de) 2005-08-18
LV13338B (en) 2006-01-20
AU663806B2 (en) 1995-10-19
JPH06263723A (ja) 1994-09-20
NZ257755A (en) 1998-03-25
HU211619A9 (en) 1995-12-28
HU9501184D0 (en) 1995-06-28
SK53795A3 (en) 1995-09-13
CN1090272A (zh) 1994-08-03
CZ106895A3 (en) 1996-03-13
WO1994010142A1 (en) 1994-05-11
RU95109936A (ru) 1997-01-10
CN1043884C (zh) 1999-06-30
EP0595557B1 (de) 2004-06-30
CY2529B1 (en) 2006-04-12
RU2148056C1 (ru) 2000-04-27
FI951992A0 (fi) 1995-04-26
CA2108584C (en) 1998-11-24
EP0595557A1 (de) 1994-05-04
IL107321A (en) 1998-08-16
DZ1724A1 (fr) 2002-02-17
HRP931309A2 (en) 1997-02-28
NO951593D0 (no) 1995-04-26
TW275621B (de) 1996-05-11
NO951593L (no) 1995-06-23
MX9306666A (es) 1994-04-29
ATE270273T1 (de) 2004-07-15
CA2108584A1 (en) 1994-04-28
HUT72084A (en) 1996-03-28
ES2224095T3 (es) 2005-03-01
FI951992A (fi) 1995-04-26
IL107321A0 (en) 1994-01-25
MY128261A (en) 2007-01-31
SI9300566A (en) 1994-09-30
PL308545A1 (en) 1995-08-21
KR950704250A (ko) 1995-11-17
AU5028393A (en) 1994-05-12
NO305697B1 (no) 1999-07-12
DK0595557T3 (da) 2004-10-25
PT595557E (pt) 2004-10-29
JPH082868B2 (ja) 1996-01-17

Similar Documents

Publication Publication Date Title
CY2529B1 (en) New substituted azetidinones as anti-inflammatory and antidegenerative agents
DE68924439T2 (de) Substituierte Azetidinone als entzündungshemmende und antidegenerative Wirkstoffe.
MY138525A (en) Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
NL300060I1 (nl) Retrovirale protease remmende verbindingen.
NZ514711A (en) Compounds useful as anti-inflammatory agents
ES2101960T3 (es) Lactamas benzo-condensadas.
ATE119774T1 (de) Imidazopyridinderivate und ihre verwendung.
ATE280767T1 (de) Antidiabetische thiazolidindione und ihre herstellung
DK0597423T3 (da) Azetidinonforbindelse og fremgangsmåde til fremstilling deraf
DE69306585D1 (de) 27 hydroxyrapamycin und derivate davon
ATE141272T1 (de) Beta-lactam-verbindungen und ihre herstellung
ATE245147T1 (de) Substituierte aminochinazolinon (thion) derivate
NO895165D0 (no) Pyrazolopyridin-type mevalono-laktoner.
AR026244A1 (es) Compuestos

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 595557

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK SHARP & DOHME CORP., 07065-0900 RAHWAY, US

Effective date: 20121213

R082 Change of representative

Ref document number: 595557

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213